Find in Library

A series of new pyrazolo[4,3-<i>e</i>][1,2,4]triazine acyclonucleosides <b>2</b>&#8722;<b>5</b> and <b>8</b> were prepared and evaluated for their anticancer activity against human cancer cell lines (MCF-7, K-562) and CDK2/E, as well as Abl protein kinases inhibitors. Lipophilicity of the compounds was determined using C-18 and immobilized artificial membrane (IAM) chromatography. In order to confirm the molecular structures and synthesis pathway of new acyclonucleosides, X-ray analysis was performed for model compound <b>3</b>. Theoretical calculations at the DFT/B3LYP/6-311++G(d,p) level were used for the characterization of electronic structures of <b>1</b>&#8722;<b>8</b>. The potential antiviral activity of acyclonucleosides <b>2</b>&#8722;<b>8</b> was tested in silico using molecular docking method.